Paclitaxel poliglumex vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): the STELLAR 2 phase III study

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [1] XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC):: The STELLAR 2 phase III study
    Bonomi, P
    Paz-Ares, L
    Langer, C
    O'Brien, M
    Gervais, R
    Gatzemeier, U
    Reiterer, R
    Orlov, S
    Ross, H
    Vandenbulcke, J
    LUNG CANCER, 2005, 49 : S35 - S35
  • [2] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    Paz-Ares, L.
    Ross, H.
    O'Brien, M.
    Riviere, A.
    Gatzemeier, U.
    Von Pawel, J.
    Kaukel, E.
    Freitag, L.
    Digel, W.
    Bischoff, H.
    Garcia-Campelo, R.
    Iannotti, N.
    Reiterer, P.
    Bover, I.
    Prendiville, J.
    Eisenfeld, A. J.
    Oldham, F. B.
    Bandstra, B.
    Singer, J. W.
    Bonomi, P.
    BRITISH JOURNAL OF CANCER, 2008, 98 (10) : 1608 - 1613
  • [3] Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
    L Paz-Ares
    H Ross
    M O'Brien
    A Riviere
    U Gatzemeier
    J Von Pawel
    E Kaukel
    L Freitag
    W Digel
    H Bischoff
    R García-Campelo
    N Iannotti
    P Reiterer
    I Bover
    J Prendiville
    A J Eisenfeld
    F B Oldham
    B Bandstra
    J W Singer
    P Bonomi
    British Journal of Cancer, 2008, 98 : 1608 - 1613
  • [4] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [5] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [6] IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Chen, Gongyan
    He, Jianxing
    Feng, Jifeng
    Zhang, Yiping
    Jiang, Liyan
    Pan, Hongming
    Chang, Jianhua
    Fang, Jian
    Cai, Amy
    Bu, Lilian
    Shi, Jane
    Xia, Jinjing
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (02)
  • [7] A PHASE II STUDY OF DOCETAXEL MONOTHERAPY IN SECOND-LINE TREATMENT IN PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Reza, M. S.
    Hai, M. A.
    Chowdhury, Q.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 120
  • [8] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [9] Pemetrexed vs docetaxel cost analysis in second-line non-small cell lung cancer treatment
    Ravasio, Roberto
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (02) : 119 - 126
  • [10] Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
12345